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Abstract
Background In response to increased case numbers of
meningococcal group C disease, catch-up vaccination
strategies have been shown to be successful. This paper
describes the results of a repeat vaccination program in
Galicia, Spain, and the strategy used for it.
Methods and results Three vaccination waves were per-
formed: first, in 1996/1997 with a meningococcal group A
and C polysaccharide vaccine in individuals aged 18 months
to 19 years; second, in 2000 with a conjugate serogroup C
polysaccharide vaccine in children born since 1993 and all
children and adolescents up to 19 years not previously
vaccinated; third, a campaign in 2006 that became
necessary because of the development of a new Neisseria
strain and an increase in both the incidence and lethality of
meningococcal C disease. The conjugate vaccine de-O-
acetylated group C meningococcal polysaccharide coupled
to tetanus toxoid was used (GCMP-TT; brand name,
NeisVac-C). Results: Applying a strategy based on model
calculations derived from the UK setting and focusing on a
population aged 13–25 years, including students, employ-
ees of companies, and underage individuals, a total of
286,000 subjects were vaccinated, resulting in global
vaccination coverage of 82.2% (all age groups over 74%).
Only 17 adverse events in 17 individuals were reported,
which all were mild. Incidence of meningococcal disease
serogroup C by season was reduced from 0.84 cases per
100,000 in 2004/05 to 0.76 cases per 100,000 in 2005/2006
to 0.18/100,000 in 2007/08. In parallel, mortality was also
decreased from 8 cases during 2005/06 (0.29 per 100,000)
to 1 case in 2007/2008 (0.03 per 100,000). No cases of
breakthrough disease occurred in the vaccinated population.
Conclusion In Galicia, a series of vaccination campaigns,
particularly focusing on high-risk groups, has shown high
effectiveness, with a marked reduction in the disease
incidence in the vaccination cohort accompanied by a
relevant reduction in the overall population.
Keywords Vaccination.Meningococcal disease.Public
health.Conjugated vaccines
Introduction
Neisseria meningitidis is the leading cause of bacterial
meningitis and septicemia in children and adolescents. It is
associated with a high mortality rate of 10–15% and
substantial morbidity rate; approximately 20% of survivors
develop permanent sequelae (Rosenstein et al. 1999). The
implementation of effective vaccination programs is key to
controling meningococcal disease (Trotter and Ramsay
2007). While at least 13 serologically distinct groups are
known, the great majority of invasive meningococcal
disease is caused by the serotypes A, B, C, W135 and Y,
with a preponderance of serotype B, although serotype C
still has an important disease impact in European countries.
Thus, meningococcal conjugate vaccines against only
serogroup C are in widespread use.
Plain meningococcal group A and C polysaccharide
vaccines are of limited value for routine immunization.
They are poorly immunogenic in infants and children under
2 years of age, the age group at highest risk of contracting
meningococcal disease. In addition, the immune response
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vaccination is known to result in immunologic hypores-
ponsiveness (De Wals et al. 2001, Granoff et al. 1998,
World Health Organization 2002). Conjugated polysaccha-
ride vaccines, in which the capsular polysaccharide is
covalently conjugated to a carrier protein, eliciting both B-
and T-cell responses, are highly immunogenic in children
younger than 2 years of age and have been shown to induce
immunologic memory (Borrow and Findlow 2009).
Therefore, meningococcal conjugate vaccines are suitable
for use in routine childhood vaccination.
Also in Galicia—an autonomic administrative region in
the northwest of Spain—meningococcal disease is endemic.
Galicia has a meningitis surveillance system, and since
1995 it also has had an active surveillance system based on
cases reported on a weekly basis by hospitals. Between
1990 and 1995 the incidence rate was about 3.5 cases per
100,000 individuals, and thus slightly higher than the
average rate in Spain (3.1 cases/100,000). The majority of
cases were caused by serogroup B. However, in 1995/96
the incidence of meningococcal disease rose sharply from
3.5 to 11.3 cases per 100,000, and 83% of cases were
caused by serogroup C [most frequent strain C:2b:P1.2,5,
cluster A4, ST-8; (BEG 1996)]. Fatal cases occurred in
children and adolescents; there was heavy media coverage
and considerable social alarm.
The case definition was considered to be Neisseria
meningitidis when at least one of the following occurred:
Confirmed cases came from microbiology laboratories of
hospitals in the region. Some specimens were sent to the
National Epidemiology Center for validation. Usually there
was agreement between the National Epidemiology Center
and the regionally confirmed cases, with only one case
about which there was not agreement.
Vaccination campaign phase I in 1996/1997
In response to the situation, the Galician Regional Public
Health Authorities assessed different control and contin-
gency plans and decided to conduct a vaccination campaign
between December 1996 and January 1997, using a
meningococcal group A and C polysaccharide vaccine,
the sole vaccine available at that time, that targeted all
residents of Galicia aged 18 months to 19 years born after
1977 (Aboal Viñas et al. 1999). This resulted in a high
coverage rate of more than 85% of the target population
and served as a template that later was followed by the
majority of other regions in Spain. As a consequence of this
vaccination campaign, the incidence of meningococcal C
disease was significantly reduced from 4.2 cases per
100,000 in the 1996/1997 season to 1.2 cases per 100,000
in the 1997/1998 season (the epidemiologic season goes
from week 41 of 1 year to week 40 of the following year)
and also a reduction in the number of suspected cases not
confirmed microbiologically from 187 in 1996 to 148 in
1997. At the same time, serogroup C mortality decreased
from 19 deaths in 1996 to 8 in 1997 (0.55 deaths per
100,000 in the 1996/1997 season to 0.22 in the 1997/1998
season). No changes were observed in the incidence of
meningococcal B disease (BEG 1998) (Fig. 1).
Vaccination campaign phase II in 2000
In November 2000, once the MenC conjugate vaccine was
available, it was included in the routine infant vaccination
calendar at 2, 4 and 6 months of age. At the same time, the
Galician Regional Public Health Authorities carried out a
second phase of the meningococcal C vaccination cam-
paign for children born after 1 January 1993 and vaccina-
tion of all children and adolescents up to 19 years of age
who had not received any dose of the polysaccharide
vaccine in the previous campaign. At the end of 2003, this
schedule was shortened to two vaccinations at 2 and
4 months, as approved in the Summary of Product
Characteristics of one of the meningococcal conjugate
vaccines used. The catch-up vaccination combined with
the amended routine infant vaccination calendar resulted in
a significant decline in the number of laboratory-confirmed
cases of group C meningitis in all age groups targeted for
vaccination (Table 1).
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Fig. 1 Incidence (cases per 100,000 inhabitants in Galicia) of
meningococcal disease between 1995 and 2008, of serogroups B, C
and not confirmed cases. Solid lines are laboratory-confirmed cases;
dotted lines denote suspected (unconfirmed) cases that occurred in
addition to confirmed cases
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– Isolation of Neisseria meningitidis in a totally sterile
environment.
– Detection of the Neisseria meningitidis genome in a
sterile environment.
– Detection of Neisseria meningitidis in CSF (cerebro-
spinal fluid)
– Diplococcus gram-negative display in CSF.Vaccination campaign phase III in 2006
From 2003/2004 a slight and continuous increase in
both the incidence and the lethality of meningococcal C
disease associated with the spread of the hyperinvasive,
hypervirulent new strain [C:2a:P1.5 (ET-37, ST-11)] was
observed (Cano et al. 2004). This increase affected in
particular persons older than 13 years of age, as younger
people were already vaccinated. This trend continued in
the 2004/2005 season, and there was no reason to assume
that it would not occur again in 2005/2006 because of the
waning of protection with time and the increased
exposure (BEG 2005).
Therefore, in response to the rising incidence of
serogroup C disease, another meningococcal C vaccination
catch-up campaign was planned for 13–25-year-old sub-
jects who had not received the conjugated vaccine (born
between 1 July 1980 and 31 December 1992) with the goal
to reduce transmission and establish herd immunity.
The target population of this campaign was determined
because the incidence increase was concentrated in people
born before 1993, which meant 83% of the cases in the
2003/2004 and 2004/2005 campaigns. From these cam-
paigns, 62% of the cases were people who had received the
polysaccharide vaccine in the 1996/1997 vaccination
campaign. At the end of the 2004/2005 campaign,
adolescents and children between 14 and 23 years of age
were the age group with a higher case incidence.
Materials and methods
Objectives
The objective of the catch-up vaccination program was to
reduce the morbidity and mortality of meningococcal
disease caused by serogroup C.
Design of vaccination program based on mathematical
modeling
Different vaccination strategies were analyzed in the
preparation phase by the government institution in charge
of vaccination programs in Galicia, Dirección Xeral de
Saúde Pública (DXSP). Trotter et al. in 2004 had
investigated the direct and indirect (herd immunity) effects
of a conjugate vaccine program in the UK and Wales [the
UK was the first country to introduce meningococcal
serogroup C conjugate vaccination in 2000 (Trotter and
Edmunds 2002)] and developed a realistic, age-structured,
dynamic mathematical model that was fitted to epidemio-
logic data (Trotter et al. 2005). The effects of a range of
vaccine strategies, including hypothetical scenarios, were
investigated using an estimated basic reproduction number
of 1.36. Of six simulated introductory vaccination strate-
gies, two were judged to be comparable to the situation in
Galicia after this new catch-up campaign; one to be
“strategy 3,” routine vaccination plus a catch-up campaign
up to 18 years of age; and another to be “strategy 4,”
routine vaccination plus a catch-up campaign up to 25 years
of age. The DXSP considered that both strategies
controlled the disease rapidly because of the catch-up
vaccination, which had a great impact on MenC transmis-
sion. Long-term results obtained with both strategies were
fully satisfactory and the main assumptions of the model
appropriate.
However, there were two main differences between the
model and the situation in Galicia, which were not
considered to be an obstacle for the adoption of the models.
First, the Galician population is older than the English and
Welsh population, a difference that probably could lead to a
lower prevalence of carriers among the total population;
however, the difference was considered not to be relevant
for the target populations of the program (adolescents). If
the contact patterns between people were proportional to
Table 1 Laboratory-confirmed cases of serogroup C meningococcal disease in Galicia by age group and year
Season
95/96 96/97 97/98 98/99 99/00 00/01 01/02 02/03 03/04 04/05 05/06 06/07 07/08
Age
< 2 3 3 3 7 2 1 4501000001
2–4 3 7 1 9 42300022201
5–9 2 2 1 3 21720101131
10–1 4 1 6 501100213001
15–1 9 1 8 1 6 11022228300
20–2 4 2301101021301
> 2 4 92 0 612072681 2 60
A l l1 3 7 1 1 3 3 41 11 94 1 17 1 32 32 19 5
J Public Health (2011) 19:409–415 411age, a different age structure might result in a different
pattern of effective contacts. However, there is evidence
indicating that contact patterns are assortative, i.e., the
frequency of contacts within a given age group is higher
than in other age groups. Assuming an assortative contact
pattern, the difference in the age structures between the
populations in Galicia and those in England and Wales can
be neglected. Second, the carrier prevalence of Neisseria
lactamica and Neisseria meningitidis other than C
serogroup could be assumed to be equivalent. This was
because the investigation of carriers in Galicia during the
vaccination campaign of 1996/97 gave similar results to the
one used in the model (Fernandez et al. 1999). Up to 2005
the incidence of meningococcal disease caused by
serogroups other than C was stable (Fig. 1). On the
contrary, after the two vaccination campaigns there were
no carrier prevalence data on meningococcus C in Galicia,
although there are indications that allow assuming that the
initial conditions were not very different. Initially, 1 year after
the first vaccination campaign in 1996/97, the prevalence of
adolescent carriers of meningococcus serogroup C was
significantly lower compared to pre-campaign levels. Further,
1 year after the campaign the incidence of meningococcal C
disease was drastically reduced (Table 1), also in age groups
without vaccination, which can be explained by a decline in
exposure to N. meningitides serogroup C—induced by
vaccination or spontaneous.
Notably, with the introduction of conjugated vaccine and
its high acceptance in Galicia (as evidenced by high
vaccination coverage), the most informative group for the
estimate of exposition was lost. In 2004/2005 in Galicia
similar rates were observed as in the UK in 1998/1999
(Trotter et al. 2002): 5.8 versus 7.9 cases/100,000 inhab-
itants (age 15–19 years) and 2.3 versus 1.9 (age 20–24
years). Further, as in the UK at the end of the 1990s, in
Galicia the increased case number was associated with
strain ST-11 complex ET-37, C: 2a:P1.5.
On the basis of these data, the DXSP decided to
implement a strategy (“number 4”) with routine vaccination
plus the vaccination of individuals<26 years, aiming at
vaccination coverage as established in the model calcula-
tion (Table 2). The higher age range was chosen in order to
offset the shortfall in recruitment as during the first
vaccination campaign only 50% of the subjects aged 18–
19 years had been vaccinated.
The program had to generate two effects, a direct effect
through individual immunity and an indirect effect by
generation of herd immunity. According to the model, herd
immunity could be generated only if the vaccination
coverage in the different age groups was achieved. For this
reason, minimum vaccination coverage was predefined by
different groups of age (Table 2). These coverage rates had
to be high enough to stop transmission.
Target population
All individuals born within 1 July 1980 to 31 December
1992 (aged 13–25 years) were included. The only applica-
ble criterion for non-eligibility for this vaccination was the
presence of a contraindication for meningococcal C
vaccination such as pregnancy or allergy to any of the
components of the vaccine. Immunosuppressant subjects
could be vaccinated; HIV infection was no contraindication.
The definition of the target group was designated taking
into account the epidemiology of the disease in Galicia and
the population suffering from the illness during the 2004/05
season and considering that the previous vaccination
campaign against meningococcus C had been directed at
children born after 1 January 1993. In 2004/05 in Galicia
more than 55% of meningococcal disease attributable to
serogroup C occurred in the age range of 13–25 years old,
but only 10% in younger individuals. The main risk of
considering this target is not achieving the intended
coverage. Because of the model used, the coverage is a
fixed value; therefore, if this coverage is not reached, the
results will not be valid. For this reason, different strategies
to reach a high number of individuals had to be
implemented.
Vaccine
In the campaign conjugate vaccine de-O-acetylated group C
meningococcal polysaccharide coupled to tetanus toxoid
was used (GCMP-TT; brand name: NeisVac-C, manufac-
turer: Baxter BioSience, Vienna, Austria) (Pollabauer et al.
2005). Extensive evidence has been accumulated on the
immunogenicity, safety and posology of GCMP-TT as well
as its epidemiological impact. The pooled protection rate,
defined as the proportion of subjects with serum bacteri-
cidal antibody (SBA) levels≥1:8, was 99.4% (CI: 98.2–
99.9%) in seven clinical trials covering all age groups.
After a catch-up vaccination campaign in the UK (where 5–
8-year-old children were primarily given GCMP-TT),
vaccine effectiveness in the target population (i.e., 2-
month-old infants to 18-year-old adolescents) was 95%
(CI: was 92–97%) within 1 year and 90% (CI: 83–94%)
more than 1 year after vaccination. Furthermore, a routine
immunization program using a one-dose GCMP-TT vacci-
nation at the age of 14 months was introduced in 2002 in
The Netherlands. In parallel a catch-up campaign targeting
all children from 1–18 years was conducted.
In addition to this data, no vaccination failure occurred
in people vaccinated with NeisVac-C by the time of making
the decision for the vaccine to be used during the campaign.
Another factor that contributes to the high immunoge-
nicity is the choice of the carrier protein that may derive
from enhanced T-cell priming by the TT carrier; the TT
412 J Public Health (2011) 19:409–415carrier is very stable, so the vaccine remains stable at high
temperatures. This vaccine can be stored for 9 months out
the refrigerator, which contributes to the logistics and the
cost reduction of a catch-up vaccination campaign.
Logistics of the campaign
This catch-up vaccination campaign lasted 21 weeks from 6
February 2006 to 30 June 2006. During the entire period,
the catch-up campaign was performed in parallel with the
primary immunization of infants at 2 and 4 months of age.
Vaccines were automatically supplied to public primary
care centers in adequate quantities to cover the first needs
of the campaign, and further supplies were delivered
according to the needs communicated to the DXSP. In
private vaccination points, vaccines were supplied after a
previous request for doses given to the DXSP. A mailing
was sent to all general doctors, pediatricians, nurseries and
primary care pharmacists explaining the justification,
vaccine to use, schedule, precautions and possible adverse
events, target population, dates and logistics of the
campaign. Such information was also distributed to public
and private vaccination centers, including hand-out materi-
als to facilitate the access to the vaccination (letter of
presentation of the campaign, instructions, numeric regis-
ters of the administered vaccine, brochures including
information about the campaign, posters, vaccination cards
for adults and adolescents, pre-paid postage envelopes). All
materials were prepared by the DXSP staff, and material
distribution was completed by the end of January.
The aim was to inform as many possible vaccination
points as possible as well as individuals in the target
population about the campaign and to offer the vaccination.
Focu was placed on certain risk groups who were
specifically targeted: the population aged 13–25 years
including students, employees of companies and underage
individuals. To facilitate the access to vaccination for
students, an agreement between the Education and Health
Departments was signed with the intention to administer the
vaccine in the education centers (schools, colleges, profes-
sional colleges and universities) using special vaccination
equipment. Furthermore, exclusive information materials
for professors, students and their parents were distributed.
Children and adolescents under 18 years were only
vaccinated if informed consent of parents was available
(but received information material in any case). Social care
centers for children under the age of 18 years (Centros de
menores) were also a special objective of this campaign, as
the majority of the people who live there are a risk
population. Special vaccination staff was sent to these
centers and followed the same instructions as for colleges.
Disabled people aged 13 to 25 years were considered a
target group in which a special strategy could increase
vaccination coverage. For that reason, before the vaccina-
tion date, information materials were distributed to these
centers where vaccination was administered by medical
personnel of the center or by special vaccination staff.
Companies with adequate medical or paramedical staff
could perform vaccination themselves for the target
population, and vaccines were supplied directly to the
companies together with the information and documenta-
tion materials.
Apart from these specific measures intended to increase
coverage, a numeric registration system of the administered
vaccines was set up to guarantee the records of coverage
achieved and to have robust records to evaluate catch-up
vaccination measures if needed. In order to obtain consis-
tency of this vaccination in the future, vaccinations were
recorded (together with the age group of the vaccinee) on a
vaccination card and in the clinical charts of the individual.
This documentation was to be sent to the DXSP.
Results
Coverage
In total, the following centers participated in the campaign:
733 health care centers, 710 schools/colleges/professional
colleges, 3 universities, 72 social care centers, 61 centers
for disabled and 32 companies. The response rate from
these centers was 100%.
The total number of individuals vaccinated during the
campaign was 285,522. Table 2 shows the number of
individuals vaccinated during the campaign by age group.
Global vaccination coverage achieved in the campaign was
82.21%. Rates in the individual age groups are shown in
the table.
Figure 2 displays the cumulative coverage during the
vaccination weeks by age group. Already by week 5, the
coverage had reached 50% in the oldest age group and up
to 80% in the younger age groups. There were no
Age group 13–14 15 16 17 18–21 22–25 All
Coverage planned (%) 85 80 70 60 45 45 n.a.
Coverage Achieved (%) 91.0 97.3 97.6 94.7 78.6 74.1 82.2
Number vaccinees (n) 39,617 21,895 23,026 23,256 87,259 90,469 285,522
Table 2 The 2006 vaccination
coverage as planned and
achieved by group of age and
number of people vaccinated
during the campaign
n.a., not applicable
J Public Health (2011) 19:409–415 413significant differences in coverage among the four prov-
inces in Galicia.
Adverse events
Notification of adverse events was performed through the
surveillance system of adverse events after vaccination
(RASV) of the DXSP. A total of 17 adverse notification
events, from 17 different individuals, were reported, which
all were mild. Most adverse events occurred immediately
after vaccination and manifested as local reactions such as
redness, pain, edema, mild fever, headache and arthralgia.
Dizziness related to orthostatic hypotension was observed
in some school and colleges when the vaccine was
administered in the presence of other students.
Preventive effect
Incidence of meningococcal disease serogroup C of 0.84
cases per 100,000 in 2004–2005 was reduced to a rate of
0.18 per 100,000 in 2007–2008. None of the meningococ-
cal disease cases occurred in the population vaccinated
during the campaign. Figure 1 and Table 1 show the
reduction of incidence in the period after the vaccination
campaign. In parallel, mortality was also reduced from
eight cases in 2005–2006 to one case in 2007–2008.
Discussion
Galicia has a well-established epidemiological surveillance
system that provides, among others, reliable incidence rates
of meningococcal C disease. Based on these observations, a
series of successful vaccination campaigns was launched in
1996.
The DXSP considered the incidence increase of menin-
gococcal C cases and related mortality in 2003–2004 to be
likely due to the waning of protection over time and also to
the increase in exposure. Analyses by age group provided
evidence that the population at particular risk was those
aged 13–25 years (individuals born before 1993).
The latest catch-up vaccination campaign was launched
with the expectation that the high-risk population would
obtain a double benefit by a direct effect in the vaccinated
population and by an indirect effect creating herd immunity
in the non-vaccinated population.
As reported by Trotter et al., catch-up vaccination
targeting teenagers generated substantial herd immunity
and was important in controlling disease rapidly (Trotter et
al. 2005). Our outcomes confirm that models based on
experience in comparable epidemiological settings can be
used to plan vaccination campaigns. The critical success
factor according to the model was to achieve vaccination
coverage across all age groups, which could only be
achieved by the unanimous support of the many parties
involved in this campaign. The overall coverage (and the
rates achieved in each age group) exceeds by far the
coverage that according to the model of Trotter et al. is
necessary for a marked decline of meningococcal disease
by both direct and indirect effects. (Trotter et al. 2005)I ti s
worth pointing out that the population aged 18–25 years is
recognized to be a group in which it is rather difficult to
achieve high coverage rates.
In November 2006, the routine vaccination schedule was
modified to include a booster dose in the second year of
age. This schedule was implemented as a consequence of
new findings on vaccine effectiveness in routine immuni-
zation programs in infants. The data, published in late 2004,
showed that vaccine effectiveness within 1 year of the
completion of a primary vaccination course was high
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414 J Public Health (2011) 19:409–415(93%); however, the immunity waned 1 year after comple-
tion of the primary series (Trotter et al. 2004). A booster
dose in the second year of age was recommended in order
to generate long-term protection, and the schedule was
modified to follow this recommendation to 2, 4 and
18 months of age.
Results obtained in the campaign were highly satisfactory.
Targeted vaccination coverage was clearly overachieved, and
disease incidence and mortality was reduced substantially. A
decisive factor for these results was the cooperation of all
parties involved in the campaign: health authorities, health
care personnel, vaccination centers, hospitals, responsible
persons in the education system, universities, colleges,
vaccination centers and most importantly the general public.
The vaccination campaign was very well accepted by the
public, which is reflected both in the high coverage rates and
in the development of the campaign.
Conclusion
In Galicia, the excellent results obtained in the catch-up
vaccination campaign with particular focus on groups
difficult to reach for preventive measures together with
the maintenance of routine immunization in infants has led
to a substantial reduction in the incidence of meningococcal
disease. This is attributable to the direct effect of the
vaccination on individual immunity but also to an indirect
effect, herd immunity, as a vaccination coverage necessary
to stop transmission was achieved.
Continuous epidemiological surveillance of meningo-
coccal disease presently confirms the expected benefits.
The Galician Health Authorities will continuously survey
the meningococcal C disease epidemiology to assess the
effectiveness of this vaccination campaign in the long term.
Another aspect to point out is the importance of imple-
menting specific actions for population groups whose vaccine
uptake is expected to be low. It was demonstrated in our
program that distinctively designed activities for such groups
can be successful and result in high vaccination coverage.
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